Robuschi M, Vaghi A, Simone P, Bianco S
Clin Allergy. 1987 Jan;17(1):69-74. doi: 10.1111/j.1365-2222.1987.tb02321.x.
A single dose double-blind crossover study was performed to compare the efficacy of nedocromil sodium (4 mg) and placebo administered from pressurized aerosols against bronchoconstriction induced by the inhalation of ultrasonically nebulized distilled water (fog) in twelve asthmatic subjects. Neither active nor placebo pre-treatment produced any significant change in baseline FEV1 and SRaw. Nedocromil sodium significantly attenuated fog-induced falls in FEV1 (P less than 0.001) and increased specific airways resistance (SRaw, P less than 0.01). The results provide further evidence of the potential therapeutic usefulness of nedocromil sodium in the management of chronic obstructive airways disease.
进行了一项单剂量双盲交叉研究，以比较12名哮喘患者中，从压力气雾剂给药的奈多罗米钠（4毫克）和安慰剂，对吸入超声雾化蒸馏水（雾）诱发的支气管收缩的疗效。活性药物和安慰剂预处理均未使基线第一秒用力呼气量（FEV1）和比气道阻力（SRaw）产生任何显著变化。奈多罗米钠显著减轻了雾诱发的FEV1下降（P<0.001），并增加了比气道阻力（SRaw，P<0.01）。这些结果为奈多罗米钠在慢性阻塞性气道疾病管理中的潜在治疗作用提供了进一步证据。
